CCM
INSY

Cupps Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Cupps Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4,490
Closed -$87K – 243
2014
Q3 		$87K Buy
+4,490
New +$70.5K 0.01% 176

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cupps Capital Management's INSY Position: Q4 2014 in Review

Cupps Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2014, closing a stake of 4,490 shares — an estimated $87K sold.

Cupps Capital Management first reported a position in INSY in Q3 2014 and held it in 1 quarter. The position peaked at $87K in Q3 2014. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2014.

  • Cupps Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Cupps Capital Management sold 4,490 Insys Therapeutics, Inc. shares in Q4 2014, an estimated $87K.
  • Cupps Capital Management first reported a position in Insys Therapeutics, Inc. in Q3 2014 and held it in 1 quarter.
  • Cupps Capital Management's Insys Therapeutics, Inc. position peaked at $87K in Q3 2014.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2014.

Based on Cupps Capital Management's 13F filing for Q4 2014, filed 9 Feb 2015.